The antiviral drug resistance market size is projected to reach US$ 6.35 billion by 2031 from US$ 3.44 billion in 2023. The market is expected to register a CAGR of 7.9% during 2023–2031. Rising in incidences of hepatic diseases, the prevalence of HIV and AIDS, and demand for high-quality products in emerging nations are likely to remain key trends in the market.
The prevalence of HIV/AIDS has increased in recent years worldwide. Acquired immunodeficiency syndrome (AIDS) is a chronic, potentially life-threatening condition which is caused by a human immunodeficiency virus (HIV). The virus is responsible for damaging the immune system, where HIV interferes with the body's ability to fight the organisms that cause disease. When HIV enters the body, it develops a flu-like illness within a month. This illness is known as primary or acute HIV infection that may last for a few weeks. As per the data provided by the US Department of Health & Human Services and supported and the Secretary’s Minority AIDS Initiative Fund (SMAIF), in 2022, approx. 39 million people were living worldwide with HIV/AIDS. A massive majority of people living with HIV are in low- and middle-income countries. For instance, according to the India HIV Estimation 2017 report (National Informatics Centre), in India, the prevalence of HIV is estimated at 0.22% (0.16%–0.30%). Moreover, an adult HIV prevalence is estimated at 0.25% (0.18%-0.34%) among males and at 0.19% (0.14-0.25) among Females. Hence, the cases of viral infections in the country are anticipated to drive the demand for the antiviral drug resistance market during the forecast period
Rise in the incidences of hepatitis diseases and increasing prevalence of HIV/AIDS are boosting the growth of the market over the years. Also, the increase in the emerging market is likely to have a positive impact on the demand for the market during the forecast period. However, the growth of the market is restrained by a factor such as alternative approaches. The prevalence of HIV in the US has increased during recent years. As per the data provided by the US Department of Health & Human Services and supported and the Secretary’s Minority AIDS Initiative Fund (SMAIF), almost 32,100 Americans were newly infected with HIV during 2021. Hence, the factors as mentioned above are anticipated to fuel the growth of North America antiviral drug resistance market during the forecast period.
You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities
Antiviral Drug Resistance Market: Strategic Insights
Viruses are the tinier germs that can cause several infectious diseases such as flu, common cold, and warts. Viruses can also cause severe illnesses, including smallpox, HIV/AIDS, and Ebola. Viruses reproduce inside cells and able to enter into any living, healthy cells and multiply and produce other viruses like themselves. Different viruses attack specific cells in the body such as liver, brain, skin, blood and also reproductive, respiratory, and gastrointestinal systems. The prevalence of virus infections such as hepatitis has increased during recent years across the globe. Hepatitis causes liver damage and inflammation that can also damage other organs. It is a major global health problem that can cause chronic infection and also upsurge the higher risk of death from cirrhosis and liver cancer. Hepatitis can be categorized as hepatitis A, B, C, D, and E that spread through different causes. According to the WHO (World Health Organization), the prevalence of Hepatitis B is the highest in the African and Western Pacific Region, where 6.1% and 6.2% of the adult population is infected respectively.
The increasing healthcare expenditure in emerging economies such as Asia Pacific and South and Central America are enabling researchers to develop treatment options for a wide range of viral diseases by utilizing advanced techniques such as PCR (Polymerase Chain Reaction), next-generation sequencing, and others. Several organizations such as, National Cancer Institute (NCI) funded for HIV and AIDS Malignancies Research to study about how aging in the presence of chronic HIV infections affects risk, spectrum and biology of cancer. China, Japan, Brazil and other emerging nations are spending heavily on healthcare expenditure to establish their presence in the market as well as to ensure the appropriate use of instruments and reagents used in hospitals and research institutes, pathological labs and other destinations in their respective countries.
Key segments that contributed to the derivation of the antiviral drug resistance market analysis are type, disease indication, technology, and end users.
The geographic scope of the antiviral drug resistance market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America. North America has largest market share of the high-flow nasal cannula market, by geography. The demand for the market is anticipated to grow at a substantial rate during the forecast period owing to various factors such as prevalence of viral infections such as HIV and hepatitis, presence of national programmes and funding by government bodies. The prevalence of HIV in the US has increased during recent years. As per the data provided by the US Department of Health & Human Services and supported and the Secretary’s Minority AIDS Initiative Fund (SMAIF), almost 32,100 Americans were newly infected with HIV during 2021. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.
The regional trends and factors influencing the Antiviral Drug Resistance Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Antiviral Drug Resistance Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 3.44 Billion |
| Market Size by 2031 | US$ 6.35 Billion |
| Global CAGR (2023 - 2031) | 7.9% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Product
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Antiviral Drug Resistance Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Antiviral Drug Resistance Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The antiviral drug resistance market is evaluated by gathering qualitative and quantitative data from primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the antiviral drug resistance market are listed below:
The “Antiviral Drug Resistance Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:
Based on geography, the antiviral drug resistance market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America is the largest contributor to the growth of the global antiviral drug resistance market. Asia Pacific is expected to register the highest CAGR in the antiviral drug resistance market during 2023–2031
Risisng in the incidences of hepatitis diseases followed by increasing prevalence of HIV and AIDS largely drive the antiviral drug resistance market size
The Antiviral Drug Resistance market majorly consists of players such AccuBioTech Co., Ltd.; ACON Laboratories, Inc.; Siemens AG; BioMérieux SA; Bio-Rad Laboratories, Inc.; Danaher; Abbott; BDF. Hoffmann-La Roche Ltd.; and Trinity Biotech.
The antiviral drug resistance market size is projected to reach US$ 6.35 billion by 2031
The market is expected to register a CAGR of 7.9% during 2023–2031